Every 10-Q that Integra LifeSciences Holdings (IART) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IART and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IART filings page.
Integra LifeSciences Holdings Corporation reported modestly higher revenue and a return to profitability in Q2 2026. Total revenue was $418,761 thousand for the quarter and $810,679 thousand for the first half of 2026, slightly above the prior-year periods.
Q2 2026 net income was $4,482 thousand, compared with a net loss of $484,073 thousand in Q2 2025, when results included a $511,365 thousand goodwill impairment charge. Operating income for the first half improved to $30,755 thousand from a loss of $528,171 thousand a year earlier.
Cash and cash equivalents were $214,415 thousand and short-term investments $59,669 thousand at June 30, 2026. Total debt had a carrying value of $1,872,299 thousand. Net cash provided by operating activities for the first six months was $32,605 thousand, versus $(2,338) thousand in 2025.
Integra LifeSciences delivered higher revenue but remained unprofitable for the quarter ended March 31, 2026. Total revenue rose to $391.9 million from $382.7 million a year earlier, led by Specialty Surgery at $283.1 million and Tissue Reconstruction at $108.8 million.
The company swung to operating income of $11.5 million from an operating loss of $15.5 million, helped by lower cost of goods sold and tighter operating expenses. Net loss narrowed significantly to $4.6 million, or $(0.06) per share, compared with a net loss of $25.3 million, or $(0.33) per share.
Cash generation improved, with operating cash flow of $9.8 million versus an outflow of $11.3 million in the prior-year quarter. The balance sheet showed cash and cash equivalents of $236.8 million, short‑term investments of $28.7 million, and total debt of about $1.87 billion. The company also recorded an $18.7 million IEEPA tariff refund receivable, providing a benefit to current-year costs.
Integra LifeSciences (IART) reported Q3 2025 results. Net revenue was $402,062, up from $380,834 a year ago. Operating income was $11,761 versus a loss in the prior year quarter, while net loss narrowed to $5,404 from $10,695.
Year to date, results reflect a non‑cash goodwill impairment of $511,365 recorded in Q2, driving a nine‑month net loss of $514,770. Segment mix showed strength in Codman Specialty Surgical at $292,583, led by Neurosurgery $201,563 and ENT $40,869; Tissue Technologies was $109,479.
On the balance sheet, cash and cash equivalents were $232,186 as of September 30, 2025. The company repaid convertible debt during the period, with “Convertible securities” at $0 versus $573,170 at year‑end, and long‑term borrowings under the senior credit facility rose to $1,708,851. Inventories increased to $489,106. Cash from operations for the nine months was $38,568. Shares outstanding were 77,892,111 as of October 29, 2025.